Discovery Programs
Drug Discovery
Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit to a clinically ready candidate with balanced properties and strong IP protection. We handle any type of peptide, and all our work is done in-house to ensure quality and speed.
Why Gubra?
-
Expertise in peptide drugs
-
One-stop shop for peptide drug discovery
-
AI/ML-driven drug discovery platform
-
Fast delivery of clinical candidates
-
Proven track record of successful programs


Consult with Lise Biehl Rudkjær
Director, Business Development
Choose the right, trustworthy discovery partner.
ML/AI-driven Peptide Drug Discovery
The streaMLine platform
The streaMLine platform is our ML/AI-driven platform for peptide drug discovery. We use high-throughput AI-driven data analysis and peptide library designs. We optimize several parameters in parallel to quickly obtain the best clinical candidate. All our work is done in-house to ensure its quality.

“
The streaMLine platform enables smarter and faster peptide drug discovery.
Discover our unique ML/AI-driven platform developed by in-house experts.
In-house data generation – high quality & speed
One-stop shop for peptide drug discovery
- Customized peptide libraries
- 4000+ peptides per month
- Linear peptides, cyclic peptides
- Natural & unnatural amino acids
- Half-life extenders, linkers, and fluorophore labeling
- Agonist & antagonist
- Internalization
- Protein-protein interactions
- Solubility
- Physical stability
- Chemical stability
- PK
- Metabolite identification
- Exposure analysis
- Expert CRO in rodent in vivo pharmacology
- Golden-standard models in all indications related to metabolic and fibrotic diseases
- Sophisticated in-vivo endpoints
- Supported by assay, histology, imaging and NGS facilities
- AI-driven data analyses and compound design
- A specialized team of data-scientist and software developers
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650